Orasis Pharmaceuticals
Orasis Pharmaceuticals is a venture-backed ophthalmic pharmaceutical company that developed and commercializes Qlosi, an FDA-approved pilocarpine 0.4% eye drop for presbyopia, targeting U.S. adults 40+ through eye care professionals and pharmacy partners, with international licensing in Korea and Australia.
- Company typePrivate
- Founded2018
- HeadquartersPonte Vedra, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Orasis Pharmaceuticals does
Orasis Pharmaceuticals is a venture-backed ophthalmic pharmaceutical company developing and commercializing prescription treatments for presbyopia, the age-related loss of near focusing ability affecting approximately 128 million people in the U.S. and nearly 2 billion globally. The company's lead and only commercial product is Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, which received FDA approval in October 2023 and was launched in the U.S. in April 2025.
Qlosi is built on the proprietary EyeQ Formulation platform, which delivers the lowest effective concentration of pilocarpine in a preservative-free, single-use vial with near-neutral pH and dual lubricating agents (hyaluronic acid and HPMC). Its mechanism is pupil modulation creating a pinhole effect and increased depth of field; clinical data from the Phase 3 NEAR-1 and NEAR-2 trials in 600+ patients showed three-line or greater gains in distance-corrected near visual acuity, no loss of distance vision, and effects lasting up to eight hours. The pupil-selective mechanism was independently validated by the Bascom Palmer Eye Institute, distinguishing Qlosi from higher-concentration pilocarpine formulations. Orasis is also pursuing ex-U.S. regulatory and commercial expansion under the brand name BESKA (Australia TGA submission filed in July 2026) and through the licensed Qlosi brand (Korea launch planned 2026 via Optus Pharmaceuticals).
The business model combines prescription pharmaceutical sales in the U.S. with international licensing economics. U.S. revenue flows through pharmacy partners BlinkRx and Medvantx (with free home delivery, First Fill Free program, and in-office dispensing in permitted states) and is driven by a sales force targeting optometrists and ophthalmologists, supported by direct-to-consumer campaigns. International revenue is generated via licensing and milestone payments plus double-digit royalties; the Korea agreement with Optus alone carries $18 million in upfront and milestone payments. The company has raised approximately $126 million in equity and structured capital across rounds from 2016 through 2024, with a $78 million Series D in October 2024 led by Arboretum Ventures and JJDC that funded the U.S. commercial launch.
Orasis Pharmaceuticals firmographics
Firmographics- Name
- Orasis Pharmaceuticals
- Legal name
- Orasis Pharmaceuticals, Inc.
- Website
- https://orasis-pharma.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Orasis Pharmaceuticals is a venture-backed ophthalmic pharmaceutical company that developed and commercializes Qlosi, an FDA-approved pilocarpine 0.4% eye drop for presbyopia, targeting U.S. adults 40+ through eye care professionals and pharmacy partners, with international licensing in Korea and Australia.
- Ownership category
- akta.pro rank
Orasis Pharmaceuticals industry classification
Industry- Product category
- Ophthalmic Pharmaceuticals (Presbyopia Therapeutics)
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Ophthalmology Pharmaceuticals (HLAIAAAL)
- akta.pro secondary industry
- Ophthalmology Specialty Pharmaceuticals (HLAIACAK)
Keywords
Where Orasis Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Ponte Vedra
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Orasis Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Marketing or Sales, Personnel, Supply Chain, Operations
Revenue model
- Prescription Pharmaceutical Sales: Revenue generated from sales of Qlosi (pilocarpine hydrochloride ophthalmic solution 0.4%) prescribed by eye care professionals and dispensed through pharmacy partners including BlinkRx and Medvantx, as well as in-office dispensing.
- Licensing and Milestone Payments: International licensing agreements with regional partners generate upfront payments, milestone payments, and double-digit royalties on sales. Licensing agreement with Optus Pharmaceuticals for Korea includes $18 million in upfront and milestone payments plus royalties.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Standard prescription pricing through pharmacy partners |
Go-to-market motion3 records
Distribution channels6 records
Marketing channels5 records
Orasis Pharmaceuticals product offering
Product offeringCore offering
Orasis Pharmaceuticals develops and commercializes Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a prescription eye drop for the treatment of presbyopia in adults. The product uses the proprietary EyeQ Formulation to deliver the lowest effective concentration of pilocarpine in a preservative-free, near-neutral pH solution with dual lubricating agents, improving near vision through pupil modulation. Orasis sells Qlosi through eye care professionals and pharmacy partners in the U.S., with international commercialization handled through licensing agreements.
Product overview
Orasis Pharmaceuticals is an ophthalmic pharmaceutical company with a single core product: Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a prescription eye drop for presbyopia treatment. The product uses the proprietary EyeQ Formulation delivering the lowest effective concentration of pilocarpine in a preservative-free, near-neutral pH formulation with dual lubricating agents. Qlosi is complemented by patient support offerings including the Clear Start Kit for first prescriptions and Starter Packs for eye care professionals. The company operates a pharmacy partnership model through BlinkRx and Medvantx for prescription fulfillment. Internationally, the same formulation is marketed as BESKA in markets like Australia and Korea under licensing agreements.
Differentiator
Problem solved
Functional benefit
Brands
- EyeQ Formulation: Proprietary formulation technology delivering the lowest effective concentration of pilocarpine in a preservative-free eye drop with near-neutral pH and dual lubricating agents for enhanced safety and patient comfort
Products and services
- Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% Prescription eye drop for the treatment of presbyopia in adults. Uses the proprietary EyeQ Formulation delivering the lowest effective concentration of pilocarpine (0.4%) in a preservative-free, near-neutral pH single-use vial with dual lubricating agents (hyaluronic acid and HPMC). Improves near visual acuity through pupil modulation (pinhole effect) without impacting distance vision, with effects lasting up to 8 hours from one or two drops daily.
Quantifiable outcome
- 3-line or more gain in distance-corrected near visual acuity (DCNVA)
- +5 more outcomes
Companies that use Orasis Pharmaceuticals
Customer profileSegments1 record
Ideal customer profiles2 records
Orasis Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Orasis Pharmaceuticals partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major and core.
- Aspen Pharmacare AustraliamajorSubmitted New Drug Application in Australia to TGA for BESKA (Qlosi) for presbyopia treatment. One of Australia's leading pharmaceutical companies with over 150 prescription and OTC medicine brands. Will be responsible for distribution and marketing in Australia.
- BlinkRxcorePrimary pharmacy partner for prescription fulfillment with integrated data-driven technology. Offers free home delivery, First Fill Free program for new prescriptions, and personalized patient support. Streamlines prescription journey management across all stakeholders.
- MedvantxmajorPharmacy partner providing prescription fulfillment with home delivery options for Qlosi prescriptions.
- Optus PharmaceuticalscoreExclusive licensing agreement for commercialization in Korea. Includes $18 million in upfront and milestone payments plus double-digit royalties on sales. Korean-based pharmaceutical company specializing in total eye care. Plans to launch Qlosi in Korea by 2026 after regulatory approval.
Scale indicators8 records
Recent moves9 records
Expansion highlights5 records
Orasis Pharmaceuticals competitors and assessment
Company assessmentBroad incumbents
- AbbVie (Allergan): Through Allergan, AbbVie commercializes Vuity (pilocarpine 1.25%), the first FDA-approved presbyopia eye drop and the most direct competitor to Orasis' Qlosi. Both target the same presbyopia patient with pilocarpine-based pupil modulation, making AbbVie the most relevant peer despite its broader ophthalmic portfolio.
- Bausch + Lomb: Major diversified ophthalmic company with broad pharmaceutical, surgical, and consumer vision portfolios. Comparable as a larger ophthalmic incumbent with deep ECP relationships and the ability to bundle or compete with presbyopia therapies.
- Alcon: Global leader in ophthalmic pharmaceuticals, surgical, and vision care. Comparable as a large ophthalmic player with established ECP sales infrastructure and potentially a strategic acquirer or competitor for the presbyopia drop category.
- Novartis Pharmaceuticals (Ophthalmics): Global pharmaceutical company with a significant ophthalmic franchise focused on retinal diseases and dry eye. Comparable as a large ophthalmic incumbent with potential strategic interest in the presbyopia category.
Direct peers
- LENZ Therapeutics: Late-stage clinical ophthalmic company developing an aceclidine-based eye drop for presbyopia. Direct competitor pursuing the same patient population with a different mechanism of action, with Phase 3 data and a planned NDA submission.
Emerging players
- Visus Therapeutics: Clinical-stage ophthalmic company developing BRIMOCHOL (carbachol + brimonidine) for presbyopia, with Phase 3 data. Directly competes in the presbyopia eye drop category with a non-pilocarpine mechanism.
- Eyenovia: Clinical and commercial ophthalmic company developing therapeutics including for presbyopia using its proprietary Optejet dispensing platform. Comparable in focus on presbyopia drug delivery and novelty in ophthalmic administration.
- Ocuphire Pharma: Late-stage ophthalmic company developing therapeutics for refractive and pupil modulation indications, including presbyopia programs. Comparable as a small-cap ophthalmic drug developer targeting eye care professionals.
- Tarsus Pharmaceuticals: Commercial-stage ophthalmic company with a launched prescription eye drop (Xdemvy for Demodex blepharitis). Comparable as a comparable-sized, ECP-focused ophthalmic launch story with a single specialty product.
Others
- Glaukos Corporation: Specialty ophthalmic company focused on interventional treatments for glaucoma and other eye disorders. Comparable as a publicly traded interventional/commercial ophthalmic peer and as a potential acquirer of complementary ophthalmic franchises.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Orasis Pharmaceuticals social profiles
Digital presenceOrasis Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Orasis Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles10 records
Orasis Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds5 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Orasis Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Orasis Pharmaceuticals
What does Orasis Pharmaceuticals do?
Orasis Pharmaceuticals develops and commercializes Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4%, a prescription eye drop for the treatment of presbyopia in adults. The product uses the proprietary EyeQ Formulation to deliver the lowest effective concentration of pilocarpine in a preservative-free, near-neutral pH solution with dual lubricating agents, improving near vision through pupil modulation. Orasis sells Qlosi through eye care professionals and pharmacy partners in the U.S., with international commercialization handled through licensing agreements.
Is Orasis Pharmaceuticals a public or private company?
Orasis Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was Orasis Pharmaceuticals founded?
Orasis Pharmaceuticals was founded in 2018. It employs 51 to 100 people.
Where is Orasis Pharmaceuticals based?
Orasis Pharmaceuticals is headquartered in Ponte Vedra, United States, in the North America region.
How does Orasis Pharmaceuticals make money?
Two revenue lines are on record. Prescription Pharmaceutical Sales are the primary driver. The others are licensing and Milestone Payments.
Who are Orasis Pharmaceuticals's main competitors?
Broad incumbents on record are AbbVie (Allergan), Bausch + Lomb, Alcon and Novartis Pharmaceuticals (Ophthalmics). LENZ Therapeutics is listed as a direct peer. Emerging players are Visus Therapeutics, Eyenovia, Ocuphire Pharma and Tarsus Pharmaceuticals. Glaukos Corporation is listed as an others.
Does Orasis Pharmaceuticals have an API?
No public API is recorded for Orasis Pharmaceuticals.
What industry is Orasis Pharmaceuticals in?
Orasis Pharmaceuticals's product category is Ophthalmic Pharmaceuticals (Presbyopia Therapeutics). Its primary akta.pro industry code is HLAIAAAL, Ophthalmology Pharmaceuticals, with a secondary code of HLAIACAK, Ophthalmology Specialty Pharmaceuticals. Its NAICS code is 3254 and its SIC code is 2834.